loading page

New frontiers in CRISPR/Cas9 delivery systems delivery for gene editing
  • +14
  • Kazem Khoshaman,
  • Mahbobeh Nasiri,
  • Maryam Rezaee,
  • Farideh Izadi,
  • Arian Mehrara,
  • Ladan Sadeghi,
  • Yaghoub Rezaeian,
  • Esmail Rezaei,
  • Elmira Zarei,
  • Samira Rahmanian,
  • Yadollah Dalvand,
  • Marjan Shaheli,
  • Azam Rezaei,
  • Mehran Honarvar,
  • Heydar Aqababa,
  • Majid Saeedi,
  • Shayan Khalili alashti
Kazem Khoshaman

Corresponding Author:[email protected]

Author Profile
Mahbobeh Nasiri
Author Profile
Maryam Rezaee
Author Profile
Farideh Izadi
Author Profile
Arian Mehrara
Mazandaran University of Medical Sciences
Author Profile
Ladan Sadeghi
Author Profile
Yaghoub Rezaeian
Author Profile
Esmail Rezaei
Author Profile
Elmira Zarei
Author Profile
Samira Rahmanian
Author Profile
Yadollah Dalvand
Author Profile
Marjan Shaheli
Author Profile
Azam Rezaei
Author Profile
Mehran Honarvar
Author Profile
Heydar Aqababa
Author Profile
Majid Saeedi
Author Profile
Shayan Khalili alashti
Author Profile


Since its discovery in early 1980s to date, our knowledge about CRISPR has evoloved so much. CRISPR/Cas system confers the immunization ability against phages to the bacteria and is comprised of three stages: acquisition, biogenesis, and interference. It was first in 2012 when Charpentier and Doudna proposed Cas9 enzyme as a novel gene editing tool. They opened a new gate on the way of gene editing which led to new discoveries as well as novel treatments for diseases. It must be taken into consideration that the delivery of CRISPR/Cas9 remains a great barrier on the way of mass clinical exploition. The delivery of CRISPR/Cas9 requires a cargo and a vehicle. There are three types of cargos: plasmids, mRNAs, and enzymes. There two main types of vehicles as well: viral and non-viral. Non-viral delivery can be subdivided into physical and various nanoparticle mediated delivery. In this systematic review, we aimed to give an overall insight to the all delivery methods used for the delivery of CRISPR/Cas9 used for gene editing both in-vitro and in-vivo. We conducted a thorough search from two databases: Medline and scopus. After the screening Process we found 77 eligible papers and the results are illustrated in table 1,2, and 3.